|
|
Efficacy and Safety of Bosentan Combined with Treprostinil in the Treatment of Pulmonary Arterial Hypertension |
CHEN Tingting, XU Yanna, CHEN Lihang |
Zhujiang Hospital, Southern Medical University,Guangdong Guangzhou 510000, China |
|
|
Abstract Objective: To investigate the efficacy and safety of macitentan combined with tadalafil in the treatment of pulmonary arterial hypertension. Methods: 80 patients with pulmonary arterial hypertension were selected as the research subjects of this prospective study. The case collection time was from March 2021 to March 2022. All included cases were screened according to the inclusion and exclusion criteria. The 80 patients were divided into a control group and an experimental group of 40 patients each, and the grouping method was a simple randomized grouping method. The control group was treated with oral tadalafil tablets, and the observation group was treated with macitentan tablets on top of the control group. Both groups were treated for 12 consecutive weeks. The echocardiographic indexes such as pulmonary artery flat pressure (MPAP), mean systemic arterial pressure (MSAP), systemic circulation resistance (SVR) and pulmonary circulation resistance (PVR) were compared between the two groups before and after treatment, and the six-minute walk distance test (6MWD) and the Borg dyspnoea score were compared, and serum vascular endothelial factor-1 (ET) and C-reactive protein (CRP) levels were compared between the two groups of patients. The safety of the two groups of patients during treatment was compared. Results: MPAP, MSAP, SVR and PVR were lower in both the control and test groups at the end of treatment compared to the pre-treatment period, and the difference in MPAP, MSAP, SVR and PVR was more significant in the test group compared to the control group before and after treatment (P<0.05). After treatment, MPAP, MSAP, SVR, PVR in the control group and the test group were lower than those before treatment, and MPAP, MSAP, SVR, PVR in the test group were more significant than those before treatment (P<0.05). After treatment, Borg scores of the control group and the test group decreased compared with those before treatment, and Borg scores of the test group were more significant than those of the control group before and after treatment (P<0.05). After treatment, 6MWD of the control group and the test group increased compared with those before treatment, and 6MWD of the test group was more significant than those of the control group before and after treatment (P<0.05). After treatment, the levels of serum ET-1 and CRP in the control group and the test group were lower than those before treatment, and the levels of serum ET-1 and CRP in the test group were significantly lower than those in the control group (P<0.05). There were no adverse events in both groups during the treatment. Conclusion: Macitentan combined with tadalafil in the treatment of pulmonary hypertension can significantly reduce hemodynamic indexes, improve respiratory symptoms, reduce inflammatory response, and the treatment is safe.
|
|
|
|
|
[1] McGoon M D,Benza R L,Escribano-Subias P,et al.Pulmonary arterialhypertension epidemiology and registries[J].Am Coll Cardiol,2013,62(25Suppl):51-59. [2] 郑俊敏,余雄杰,连姝文.安立生坦联合他达拉非治疗肺动脉高压的有效性和安全性研究[J].中国医药科学,2019,9(20):7-12,16. [3] 陈扬航.曲前列尼尔在中高危肺动脉高压患者中的应用:单中心回顾性研究[D].广州医科大学,2021. [4] 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会,肺栓塞与肺血管病工作委员会,等.中国肺动脉高压诊断与治疗指南(2021版)[J].中华医学杂志,2021,101(1):11-51. [5] 龙愉良,周达新.他达拉非在肺动脉高压治疗中的研究进展[J].中国临床药学杂志,2021,30(4):310-316. [6] 付文海,陈沛玲,夏嘉俐,等.内皮素受体拮抗剂联合5型磷酸二酯酶抑制剂治疗动脉性肺动脉高压疗效与安全性:网状Meta分析[J].中华结核和呼吸杂志,2022,45(2):158-170. [7] 郭思彤,顾智淳,陈晓宇,等.内皮素受体拮抗剂治疗肺动脉高压的有效性和安全性的系统评价[J].医药导报,2022,41(2):206-212. [8] 申妮睿,王青婷,李满祥.内皮素-1在肺动脉高压发病机制中的研究进展[J].国际心血管病杂志,2022,49(1):14-16,24. [9] 朱敏锋,钱文霞,陈丽秀,等.C反应蛋白、脑利钠肽前体、D-二聚体在慢性阻塞性疾病伴肺动脉高压患者中的临床意义[J].当代医学,2020,26(22):88-90. |
|
|
|